Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Dhanvantri Jeevan Rekha's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:531043's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.96 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Dhanvantri Jeevan Rekha 5-Year Yield-on-Cost % Related Terms
BOM:531043 vs HCA, THC, EHC: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, Dhanvantri Jeevan Rekha's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dhanvantri Jeevan Rekha 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dhanvantri Jeevan Rekha's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Dhanvantri Jeevan Rekha's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Dhanvantri Jeevan Rekha (BOM:531043) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dhanvantri Jeevan Rekha and its competitors. According to the industry distribution chart, Dhanvantri Jeevan Rekha ranks #999999 out of 281 companies in the Healthcare Providers & Services industry.
Is Dhanvantri Jeevan Rekha's 5-Year Yield-on-Cost % too high?
Dhanvantri Jeevan Rekha's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Dhanvantri Jeevan Rekha ranks #999999 out of 281 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Dhanvantri Jeevan Rekha has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dhanvantri Jeevan Rekha's 5-Year Yield-on-Cost % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Dhanvantri Jeevan Rekha ranks #999999 out of 281 companies for 5-Year Yield-on-Cost %. This places Dhanvantri Jeevan Rekha in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.96, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dhanvantri Jeevan Rekha and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dhanvantri Jeevan Rekha's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dhanvantri Jeevan Rekha stock overvalued right now?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha (BOM:531043) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹28.32, compared to a current price of ₹24.50 — trading 13.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Dhanvantri Jeevan Rekha's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dhanvantri Jeevan Rekha (BOM:531043), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dhanvantri Jeevan Rekha (BOM:531043) Overvalued in 2026?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha stock appears to be undervalued.
The current stock price of ₹24.50 is trading 13.5% below its estimated GF Value™ of ₹28.32.
GuruFocus considers Dhanvantri Jeevan Rekha to be Modestly Undervalued.
Key valuation signals for BOM:531043:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹28.32 vs. price of ₹24.50 (13.5% below fair value)
No single metric tells the full story. See the BOM:531043 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dhanvantri Jeevan Rekha Ltd is engaged in providing diagnostic and therapeutic services and has extended its scope of diagnostic and hospital services by providing a fully operational Cath Lab, catering to higher end needs of the cardiac patients including Angiography, Angioplasty, Pacemaker Implantation, Valvuloplasty etc. The hospital has expanded its services to include a wide range of specialties such as Cardiology, Neurology, Orthopedics, Radiology, Gastroenterology, General Surgery, Urology, and General Medicine.
70GF Score
Get the complete analysis for BOM:531043
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531043 has been successfully added to your 
